共 73 条
[3]
Bai CB, 2002, DEVELOPMENT, V129, P4753
[8]
Ding Q, 1998, DEVELOPMENT, V125, P2533
[10]
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
[J].
JOURNAL OF CLINICAL ONCOLOGY,
2010, 28 (28)
:4339-4345